|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
51965222
???header.onlineuser??? :
1064
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"papai z"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-01-19T12:08:55Z |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
|
André, F.; Ciruelos, E. M.; Juric, D.; Loibl, S.; Campone, M.; Mayer, I. A.; Rubovszky, G.; Yamashita, T.; Kaufman, B.; Lu, Y. S.; Inoue, K.; Pápai, Z.; Takahashi, M.; Ghaznawi, F.; Mills, D.; Kaper, M.; Miller, M.; Conte, P. F.; Iwata, H.; Rugo, H. S. |
| 國家衛生研究院 |
2019-10 |
A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FO
|
Chen, LT;Hitre, E;Lee, WJ;Bai, LY;Papai, Z;Kang, SY;Dvorkin, M;Choi, HJ;Oh, SC;Artru, P;Bachet, JB |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
